Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Prader–Willi syndrome in neonates: twenty cases and review of the literature in Southern China

  • Ping Wang1, 2,
  • Wei Zhou2Email author,
  • Weiming Yuan2,
  • Longguang Huang2,
  • Ning Zhao2 and
  • Xiaowen Chen2
BMC PediatricsBMC series – open, inclusive and trusted201616:124

https://doi.org/10.1186/s12887-016-0662-2

Received: 6 September 2015

Accepted: 2 August 2016

Published: 9 August 2016

Abstract

Background

Prader-Willi syndrome is a rare genetic abnormality that can be challenging to diagnose early, but for which early interventions improve prognosis.

Methods

To improve understanding of Prader–Willi syndrome in neonates in Asia, we retrospectively analyzed the clinical records of 20 affected newborns diagnosed in the Department of Neonatology, Guangzhou Women and Children’s Medical Center, Guangzhou, China from January 2007 to December 2014 and performed a review of the relevant literature.

Results

Fourteen boys and six girls presented with hypotonia, poor responsiveness, feeding difficulty, and infrequent, weak crying. Different from western patients, the 20 Asian patients exhibited at least five of the following typical features: prominent forehead, narrow face, almond-shaped eyes, small mouth, downturned mouth, thin upper lip, and micromandible. All 14 boys had a small scrotum, including nine with cryptorchidism. Diagnoses were made with microarray comparative genomic hybridization. All 20 infants required feeding tubes. Fifteen received swallowing training immediately after admission; the period of continuous tube feeding for these patients ranged from 8 to 22 days (mean, 14 ± 5.3 days). For the five patients who did not receive swallowing training, the period of continuous tube feeding ranged from 15 to 35 days (mean, 18 ± 4.3 days). Comprehensive care measures included: giving parents detailed health education and basic information about this disease, teaching skills to promote feeding and prevent suffocation, increasing children’s passive activity, providing nutrition management for normal development, and preventing excessive or inadequate nutrient intake.

Conclusions

Neonates with Prader–Willi syndrome in Asia have hypotonia, poor responsiveness, feeding difficulty, infrequent and weak crying, genital hypoplasia, and characteristic facial features. Recognition of the syndrome in neonates with confirmation by genetic testing is essential, because early diagnosis allows early intervention. Treatment measures including swallowing training can improve prognosis, prevent growth retardation and obesity, and elevate quality of life in individuals with Prader–Willi syndrome.

Keywords

Prader–Willi syndrome Intervention Diagnosis Infant Neonatal Asia

Background

Prader–Willi syndrome (PWS) is a complex multisystem abnormality, first reported by Prader and colleagues in 1956. The syndrome is generally caused by an abnormality in the q11-13 region on paternal chromosome 15. The incidence of PWS varies in different countries from 1 in 15,000 to 1 in 25,000, with an average mortality of 3 % [13]. The main clinical features of affected individuals include hypotonia, feeding difficulty, developmental delay, short stature, abnormal behavior during the neonatal period, obesity, poor hypothalamic and gonadal development, and characteristic appearance during childhood [4]. There are few reports of the syndrome in Asia. There is currently insufficient understanding of the signs and symptoms of PWS in neonates, and the rate of early diagnosis is not high in Asia. Early diagnosis allows implementation of comprehensive treatment at an early stage, which can improve growth and minimize developmental disorders, improving prognosis. In this study we evaluated the clinical manifestations of PWS in 20 neonates who were treated in the Department of Neonatology, Guangzhou Women and Children’s Medical Center, Guangzhou, China. We also analyzed the relevant literature, and present the features of and comprehensive intervention measures for PWS in neonates in China.

Methods

Subjects

All neonates treated in the Department of Neonatology, Guangzhou Women and Children’s Medical Center, Guangzhou, China from January 2007 to December 2014 underwent comprehensive physical examination. Neonates who exhibited prominent forehead, narrow face, almond-shaped eyes, downturned mouth, thin upper lip, micromandible, and/or small scrotum, cryptorchidism and hypotonia were diagnosed with suspected PWS.

Clinical features

The appearances and characteristics in the 20 neonates with PWS were summarized and analyzed.

Examination methods

Further examinations were performed in these cases, including cranial magnetic resonance imaging; electroencephalogram; chest X-rays; ultrasonography of the cardiovascular system, urinary system and digestive system; as well as tandem mass spectrometry for congenital metabolic disorders. Affymetrix CytoScan 750K chip was used to detect the variation in patients’ genome. Parental health status was investigated to determine any history of congenital, hereditary, or familial diseases, history of pregnancy and delivery, and pregnancy complications. All 20 patients were diagnosed with PWS based on microarray comparative genomic hybridization within 2 months of birth. Comprehensive interventions were simultaneously instituted, including swallowing training and physical therapy, with regular rehabilitation assessments.

Results

General data

Fourteen boys and six girls were hospitalized during the neonatal period. Of the 20 cases, 16 were treated in the Department of Neonatology immediately after birth because of poor responsiveness. Four left the hospital after birth, but presented again because of poor feeding, one at 1 week, and the others at 2~4 weeks of age. Maternal age ranged from 19 to 38 years (mean, 31.5 ± 5.4 years). Paternal age ranged from 21 to 45 years (mean, 34.9 ± 8.2 years). Parents were generally healthy, and with no history of congenital, hereditary, or familial diseases. Mothers of six of the neonates had complained of infrequent fetal movement during pregnancy. Mothers of eight of the neonates had experienced polyhydramnios. None of the mothers had experienced pregnancy complications. Gestational age ranged from 32 to 42 weeks (mean, 38.5 ± 2.7 weeks). Four babies were born at 32~36 weeks (premature birth). The remaining 16 were full term. Five infant was delivered by spontaneous delivery; 15 were delivered by cesarean delivery. Mean birth weight was 2732 ± 265 g. Two patients were full-term small-for-gestational-age infants. Three had mild asphyxia at birth; the remaining 17 did not.

Features during the neonatal period

All 20 neonates presented with hypotonia, poor responsiveness, feeding difficulty, and infrequent and weak crying. Hypotonia resulted in the unusual sleeping posture of bilateral hip valgus and weakness of limbs (Fig. 1). All patients exhibited at least five of the following typical facial features, in order from most to least common, included: prominent forehead, almond-shaped eyes, downturned mouth, narrow face, thin upper lip, micromandible, and small mouth (Table 1, Fig. 1). All 14 boys had small scrota, including nine with cryptorchidism. The genitalia of one girl had the appearance of labia minora.
Fig. 1

Characteristic sleeping posture and scrotal and vulvar dysplasia in six neonates with Prader–Willi syndrome. ae Cases 1–5, respectively. All patients exhibited hypotonia, showing the characteristic sleeping posture of bilateral hip valgus and weakness of limbs. All patients exhibited prominent forehead, almond-shaped eyes and downturned mouth. The boys had a small scrotum. Cases 2, 4, and 5 had cryptorchidism. f Case 9, with hypotonia, bilateral hip valgus, and vulvar dysplasia

Table 1

Facial features and their prevalence among twenty neonates with Prader–Willi syndrome

Case

Gender

Prominent forehead

Narrow face

Almond-shaped eyes

Small mouth

Downturned mouth

Thin upper lip

Micromandible

1

Male

+

+

+

+

+

+

2

Male

+

+

+

+

+

+

3

Male

+

+

+

+

+

+

4

Male

+

+

+

+

+

5

Male

+

+

+

+

+

+

6

Male

+

+

+

+

+

+

7

Female

+

+

+

+

+

+

8

Male

+

+

+

+

+

+

+

9

Female

+

+

+

+

+

10

Female

+

+

+

+

+

+

11

Male

+

+

+

+

+

+

12

Male

+

+

+

+

+

+

13

Male

+

+

+

+

+

+

14

Male

+

+

+

+

+

15

Male

+

+

+

+

+

+

16

Male

+

+

+

+

+

+

17

Female

+

+

+

+

+

+

18

Male

+

+

+

+

+

+

+

19

Female

+

+

+

+

+

20

Female

+

+

+

+

+

+

Proportion

 

100 %

90 %

100 %

55 %

100 %

80 %

65 %

+: have this feature; −: do not have this feature

Treatment and examination results

All 20 patients presented with feeding difficulty and required feeding tubes. The period of continuous tube feeding ranged from 8 to 35 days (mean, 19 ± 8.5 days). Fifteen neonates received swallowing training immediately after admission. For these 15, the period of continuous tube feeding ranged from 8 to 22 days (mean, 14 ± 5.3 days). For the five patients who did not receive swallowing training, the period of continuous tube feeding ranged from 15 to 35 days (18 ± 4.3 days). One of the four premature infants received mechanical ventilation, which was removed successfully on the 2nd day after birth. No abnormal signs were detected in any of the patients on cranial magnetic resonance imaging. Electroencephalogram revealed increased slow background activity in 12 cases, mainly continuous low-amplitude electrical activity of 3–10 Hz, mixed with increased low-amplitude fast waves. Normal electroencephalogram waveforms were found in eight cases. Chest X-rays showed consolidation of both lungs in four patients, but no abnormality in the others. Echocardiography revealed patent ductus arteriosus in three cases, and patent foramen ovale in six. Ultrasonography of the urinary and digestive systems was normal in all cases. Tandem mass spectrometry showed a small amount of hydroxy acid in the urine of two patients with congenital metabolic diseases, and a small amount of α-ketoglutarate in one patient, indicating a high catabolic state. No organic acid metabolism was detected in the other 17 cases. Length of hospital stay ranged from 10 to 38 days (mean, 21 ± 8.4 days).

Genetic analysis

Genetic analysis was performed with microarray comparative genomic hybridization in all 20 neonates. There were microdeletions in the paternal 15q11-13 region in 16 cases (Fig. 2), and maternal homologous diploid in four cases.
Fig. 2

Genotype in case 4: 46,XY. arr14q32.33(106,272,897-106,927,569)×3. arr15q11.2q13.1(23,290,787-28,540,345)×1. Approximately 655-kb repeat in the q32.33 106,272,897-106,927,569 regions on chromosome 14; this repeat is polymorphic. Approximately 5.3-Mb deletion in the q11.2-q13.1 23, 290, 787-28, 540, 345 regions on chromosome 15; this deletion is pathogenic

Discussion

PWS is a complex disease affecting multiple body systems, with variable clinical features in different growth stages. Holm et al. [5] proposed the clinical diagnostic criteria for PWS in 1993. These include a series of symptoms from the perinatal period to adolescence; however, early diagnosis in neonates is difficult based on these criteria. A diagnosis of PWS is reliable at about 2.5 years of age [6], based on a limited number of clinical studies in Asia. Most cases are reported after the neonatal period. In seven studies, patient age at final diagnosis ranged from 1 to 20 years [713]; some of these patients presented because of delayed sexual development. Delays in diagnosis and treatment affect patient prognosis and quality of life. Several recent Asian studies have focused on PWS. However, most have explored the genetic diagnosis of the syndrome, and few have investigated manifestations and interventions during the neonatal period. Early diagnosis and early intervention greatly improve the prognosis of individuals with PWS. [6] Therefore, it is important to summarize the neonatal signs and symptoms of the syndrome in Asian, to perform gene detection for suspected cases, and to educate physicians, especially neonatologists, about early diagnosis and intervention.

This study demonstrated that the major clinical features of PWS in China include hypotonia, poor responsiveness, feeding difficulty, and infrequent crying; of these, hypotonia and feeding difficulty are consistent with the findings of previous studies [1416]. Because of hypotonia, both hips are slightly valgus, resulting in a characteristic sleeping posture in neonates with PWS. Less fetal movement and polyhydramnios are common during pregnancy in women carrying an infant with PWS, and are also associated with hypotonia and feeding difficulty [17]. In the present study, all male patients had a small scrotum, indicating that genital hypoplasia can be considered a reference for diagnosis of PWS in the neonatal period. This series included only six female patients, three of whom had vulvar dysplasia, so we cannot draw conclusions about female genital characteristics associated with the syndrome. A large sample study is needed.

For many years there has been controversy about the characteristic facial features of individuals with PWS. Gunay-Aygun et al. [4] retrospectively analyzed 90 cases of PWS, and confirmed that detection of the syndrome based on particular facial features had a sensitivity of only 49 %. All patients in this study exhibited at least five of the typical facial features, which is consistent with the results of a previous clinical study of five neonates with PWS [18]. These findings suggest that craniofacial features have a high specificity in neonates with PWS in Asia, and are thus very important in diagnosing the syndrome during the neonatal period. The difference of craniofacial features among studies may depend on the different races. Most previous studies [4, 5] were retrospective studies in children or adults, and did not exclude atypical craniofacial features resulting from childhood or adolescent obesity.

Wharton et al. [19] found that approximately 23 % of patients with PWS experienced birth asphyxia; however, Trifiro et al. [20] reported that patients did not suffer from perinatal asphyxia or severe respiratory distress immediately after birth. Three patients in the present study experienced mild birth asphyxia, a proportion similar to that in the report of Wharton et al. All had decreased muscle tone, color, and responsiveness, which are inherent characteristics of neonates with PWS, and have little association with intrauterine or peripartum hypoxia. None of the patients in this study experienced severe respiratory distress. Cranial computed tomography did not reveal signs of hypoxic brain damage. Therefore, we conclude that asphyxia and hypoxia at birth are not very common among neonates with PWS. A previous study demonstrated that the incidence of congenital birth defects such as congenital heart disease and spinal deformity was higher among individuals with PWS and should attract the attention of physicians [21].

Feeding difficulty is common among neonates with PWS. The proportion of neonates with PWS requiring a feeding tube is as high as 90–100 % in various studies. A previous study demonstrated that the average period of feeding tube use in neonates with PWS was 15 days (range, 0–60 days) [6]. All 20 patients in this study required a feeding tube. It reveals that the swallowing capability of PWS neonates is weak regardless of different races. The period of tube feeding was shorter for neonates who received swallowing training than for those who did not. However, the present study had a small sample size; the effect of swallowing training should be confirmed in a larger study. A correlation has been reported between delayed language development and the duration of tube feeding in neonates with PWS [6]. Thus, the period of tube feeding should be shortened, and swallowing training can be conducted at an early stage. In our present study, the patients received nasogastric tube feeding for a median duration of 18 ± 4.3 days. The duration of gastric tube feeding was similar with N. Bachere’s cohort study. The duration of gastric tube feeding tends to decrease, compared with historical cohort, with the younger neonates being less tube-fed than the older ones. This finding is of major importance, as the specific speech and language problems observed in previous patients could be worsened by a long duration of tube feeding. In the future, it would be better to try to avoid gastric feeding by teaching parents how to encourage and optimize suckling.

There is no specific treatment for PWS, so combination therapy is generally implemented. A previous study found a positive therapeutic effect associated with shortening the period of tube feeding, increasing growth in height, controlling abnormal weight gain, and promoting normal growth and development [6]. Parents need to receive detailed health education, including basic information about this disease. They also require instruction on promoting feeding and preventing suffocation, increasing children’s passive activity, providing nutrition management for normal development, and preventing excessive or inadequate nutrient intake. Exercise therapy was performed twice weekly in the present study to improve muscle tone and motor development. From the time of diagnosis, many professionals are involved in the care of children with PWS, including speech therapists, nutritionists, neurologists, psychiatrists, psychologists, and orthopedic surgeons. Previous studies have shown that the incidence of systolic dysfunction is higher in infants with PWS than in unaffected children. Thus, infants with PWS should have cardiovascular, nutritional, endocrine, and physical therapy visits every 3 months during the first year of life. Rechecks can occur every 6 months after the first year. Early diagnosis and intervention allow implementation of reasonable nutrition programs to prevent obesity, improve learning, and assist the development of speech [22, 23]. Regular and timely use of growth hormone (GH) after early diagnosis not only promotes growth and improves fat utilization, but also possibly elevates cognitive level [24, 25]. GH treatment is beneficial for children with PWS. It improves linear growth, body composition, physical strength and agility [2628]. Fat utilization and resting energy expenditure are increased by GH treatment, the latter partially explained by an increment in lean body mass [2931]. According to observational data, GH treatment is usually initiated at a mean age of 7 years, as reported by Takeda et al. [32]. Increasingly, GH treatment is initiated earlier [3335]. Published data support benefits of GH treatment when started between 4 and 6 months of age [36, 37], but some experts are currently treating from as early as 3 months. No consensus was reached on age of GH start, although all agreed to the benefits of treating before the onset of obesity, which often begins by 2 years of age. All of these should be considered by physicians in Asia, and correlated information should be sent to the patients’ parents as early as possible.

Conclusions

The early clinical manifestations of PWS are not specific, and the disorder is easily confused with other nervous system diseases, increasing the diagnostic challenge. But it still has some special features in Asian neonates. If unexplained hypotonia and feeding difficulty appear during the neonatal period, clinicians should suspect PWS. Infants who exhibit the typical craniofacial features of PWS should undergo genetic testing. When PWS is diagnosed, therapy should be instituted as early as possible. To optimize the prognosis for these patients, the period of tube feeding should be shortened and parents should be provided with health education.

Abbreviations

PWS, Prader–Willi syndrome; GH, growth hormone

Declarations

Acknowledgements

Not applicable.

Funding

The research has no source of funding.

Availability of data and materials

All data generated or analysed during this study are included in this published article.

Authors’ contributions

PW proposed the study and wrote the first draft. WZ guided the design of the study. WMY helped to draft the manuscript. LGH participated in its design and helped to revise the manuscript. NZ conceived of the study, and help the acquisition of data. XWC helped to analyze the data. All authors read and approved the final manuscript.

Competing interests

No benefits in any form have been received or will be received from any commercial party related directly or indirectly to the subject of this article.

Consent to publish

Written informed consent was obtained from the parents for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.

Ethics approval and consent to participate

The research has been approved by Guangzhou Women and Children’s Medical Center’s Ethics Committee.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
The First Affiliated Hospital of Jinan University
(2)
Department of Neonatology, Guangzhou Women and Children’s Medical Center

References

  1. Lionti T, Reid SM, Rowell MM. Prader-Willi syndrome in Victoria: mortality and causes of death. J Paediatr Child Health. 2012;48:506–11.View ArticlePubMedGoogle Scholar
  2. Vogels A, Van Den Ende J, Keymolen K, et al. Minimum prevalence, birth incidence and cause of death for Prader-Willi Syndrome in Flanders. Eur J Hum Genet. 2004;12:238–40.View ArticlePubMedGoogle Scholar
  3. Whittington JE, Holland AJ, Webb T, et al. Population prevalence and estimated birth incidence and mortality rate for people with Prader-Willi Syndrome in one UK Health Region. J Med Genet. 2001;38:792–8.View ArticlePubMedPubMed CentralGoogle Scholar
  4. Gunay-Aygun M, Schwartz S, Heeger S, et al. The changing purpose of Prader-Willi Syndrome clinical diagnostic criteria and proposed revised criteria. Pediatrics. 2001;108:E92.View ArticlePubMedGoogle Scholar
  5. Holm VA, Cassidy SB, Butler MG, et al. Prader-Willi Syndrome: consensus diagnostic criteria. Pediatrics. 1993;91:398–402.PubMedGoogle Scholar
  6. Bachere N, Diene G, Delagnes V, et al. Early diagnosis and multidisciplinary care reduce the hospitalization time and duration of tube feeding and prevent early obesity in PWS infants. Horm Res. 2008;69:45–52.View ArticlePubMedGoogle Scholar
  7. Bai JL, Wang H, Yang YL, et al. Unbalanced translocation t(5;15) in a patient with Prader-Willi syndrome. Chin J Med Genet. 2010;27:664–7.Google Scholar
  8. Fan PX, Gao CX, Zhang Q. Nursing care of a patient with Prader-Willi syndrome. Chin J Nurs. 2012;47:794.Google Scholar
  9. Shao XY, Zhang R, Hu C. Precise microdeletion detection of Prader-Willi syndrome with array comparative genome hybridization. Biomed Environ Sci. 2010;23:194–8.View ArticlePubMedGoogle Scholar
  10. Wu JJ, Qiao J, Han B, et al. Genetic diagnosis and weight loss surgery of a case of Prader-Willi syndrome. Chin J Endocrinol Metab. 2011;27:498–501.Google Scholar
  11. Xu F, Cheng DH, Di YF, et al. Identification of a cryptic 1p36.3 microdeletion in a patient with Prader-Willi-like syndrome features. Chin J Med Genet. 2010;27:524–9.Google Scholar
  12. Zhu YH, Yang DZ, Li J, et al. Insulin sensitivity in a patient with Prader-Willi syndrome. Chin J Diabetes Mellitus. 2012;4:159–61.Google Scholar
  13. Zhang YW, Hong J, Jia HY, et al. Prader-Willi syndrome: a clinical and epigenetic study of 4 cases. Shanghai Med J. 2010;33:1123–8.Google Scholar
  14. Cassidy SB, Schwartz S, Miller JL, et al. Prader-Willi syndrome. Genet Med. 2012;14:10–26.View ArticlePubMedGoogle Scholar
  15. Che N, Li X, Zhou ZS. One neonate with Prader-Willi syndrome and review of the literature. Journal of China-Japan Friendship Hospital. 2012;26:224–5.Google Scholar
  16. Zhan SN, He XY, Wang CZ, et al. Clinical phenotype study of Prader-Willi syndrome in 13 neonates. Chin J Evid Based Pediatr. 2012;7:200–4.Google Scholar
  17. Geysenbergh B, De Catte L, Vogels A. Can fetal ultrasound result in prenatal diagnosis of Prader-Willi syndrome? Genet Couns. 2011;22:207–16.PubMedGoogle Scholar
  18. Oiglane-Shlik E, Zordania R, Varendi H, et al. The neonatal phenotype of Prader-Willi Syndrome. Medical Genetics. 2006;140:1241–4.Google Scholar
  19. Wharton RH, Bresnan MJ. Neonatal respiratory depression and delay in diagnosis in Prader-Willi Syndrome. Dev Med Child Neurol. 1989;31:231–6.View ArticlePubMedGoogle Scholar
  20. Trifiro G, Livieri C, Bosio L, et al. Neonatal hypotonia: don’t forget the Prader-Willi syndrome. Acta Pediatr. 2003;92:1085–9.View ArticleGoogle Scholar
  21. Torrado M, Foncuberta ME, Perez MF, et al. Change in prevalence of congenital defects in children with Prader-Willi syndrome. Pediatrics. 2013;131:e544–9.View ArticlePubMedGoogle Scholar
  22. Eiholzer U. A comprehensive team approach to the management of patient with Prader-Willi syndrome. J Pediatr Endocrinol Metab. 2004;17:1153–75.View ArticlePubMedGoogle Scholar
  23. Marcus KA, van Alfen-van der Velden JA, Otten BJ, et al. Cardiac evaluation in children with Prader-Willi syndrome. Acta Paediatr. 2012;101:e225–31.View ArticlePubMedGoogle Scholar
  24. Al-Saleh S, Al-Naimi A, Hamilton J, et al. Longitudinal evaluation of sleep-disordered breathing in children with Prader-Willi Syndrome during 2 years of growth hormone therapy. J Pediatr. 2013;162:263–8.View ArticlePubMedGoogle Scholar
  25. Whitman BY, Myers SE. Prader-Willi syndrome and growth hormone therapy: take a deep breath and weigh the data. J Pediatr. 2013;162:224–6.View ArticlePubMedGoogle Scholar
  26. De Lind van Wijngaarden RF, Siemensma EP, et al. Efficacy and safety of long-term continuous growth hormone treatment in children with Prader-Willi syndrome. J Clin Endocrinol Metab. 2009;94:4205–15.View ArticleGoogle Scholar
  27. Festen DA, de Lind van Wijngaarden R, van Eekelen M, Otten BJ, Wit JM, Duivenvoorden HJ, Hokken-Koelega AC. Randomized controlled GH trial: effects on anthropometry, body composition and body proportions in a large group of children with Prader-Willi syndrome. Clin Endocrinol. 2008;69:443–51.View ArticleGoogle Scholar
  28. Carrel AL, Myers SE, Whitman BY, Allen DB. Benefits of long-term GH therapy in Prader- Willi syndrome: a 4-year study. J Clin Endocrinol Metab. 2002;87:1581–5.View ArticlePubMedGoogle Scholar
  29. Schoeller DA, Levitsky LL, Bandini LG, Dietz WW, Walczak A. Energy expenditure and body composition in Prader-Willi syndrome. Metabolism. 1988;37:115–20.View ArticlePubMedGoogle Scholar
  30. Van Mil EA, Westerterp KR, Gerver WJ, Curfs LM, Schrander-Stumpel CT, Kester AD, Saris WH. Energy expenditure at rest and during sleep in children with Prader-Willi syndrome is explained by body composition. Am J Clin Nutr. 2000;71:752–6.PubMedGoogle Scholar
  31. Oosterhof R, Ith M, Trepp R, Christ E, Fluck M. Regulation of whole body energy homeostasis with growth hormone replacement therapy and endurance exercise. Physiol Genomics. 2011;43:739–48.View ArticlePubMedGoogle Scholar
  32. Takeda A, Cooper K, Bird A, et al. Recombinant human growth hormone for the treatment of growth disorders in children: a systematic review and economic evaluation. Health Technol Assess. 2010;14:1–iv.View ArticlePubMedGoogle Scholar
  33. Diene G, Mimoun E, Feigerlova E, et al. Endocrine disorders in children with Prader-Willi syndrome—data from 142 children of the French database. Horm Res Paediatr. 2010;74:121–8.View ArticlePubMedGoogle Scholar
  34. Goldstone AP, Holland AJ, Hauffa BP, Hokken-Koelega AC, Tauber M. Recommendations for the diagnosis and management of Prader-Willi syndrome. J Clin Endocrinol Metab. 2008;93:4183–97.View ArticlePubMedGoogle Scholar
  35. Tauber M, Cutfield W. KIGS highlights: growth hormone treatment in Prader-Willi syndrome. Horm Res. 2007;68:48–50.View ArticlePubMedGoogle Scholar
  36. Festen DA, Wevers M, Lindgren AC, et al. Mental and motor development before and during growth hormone treatment in infants and toddlers with Prader-Willi syndrome. Clin Endocrinol. 2008;68:919–25.View ArticleGoogle Scholar
  37. Carrel AL, Moerchen V, Myers SE, Bekx MT, Whitman BY, Allen DB. Growth hormone improves mobility and body composition in infants and toddlers with Prader-Willi syndrome. J Pediatr. 2004;145:744–9.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2016